Greater trochanteric pain syndrome: focused shockwave therapy versus an ultrasound guided injection: a randomised control trial
HIP International · 2023-05 · 33 (3) · 490-499
DOI: 10.1177/11207000211060396 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift HIP International, online erschienen am 17.11.2021. Verfasst von Catriona Heaver und 6 weiteren Autor:innen. Beteiligte Einrichtung: Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK. Hauptthemen laut MEDLINE: Extracorporeal Shockwave Therapy, High-Energy Shock Waves, Arthroplasty, Replacement, Hip, Bursitis. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: orthopaedic institute limited.
Abstract (Originalsprache)
Background
Greater trochanteric pain syndrome (GTPS) is a common problem with an incidence of 1.8–5.6 per 1000 population. Physiotherapy, anti-inflammatories, corticosteroid injections and surgery have all been described in the management of GTPS, with limited, temporal success. Extracorporeal shockwave therapy (ESWT) has been proposed as a potential non-invasive management option for this difficult presentation.
Method
We ran a prospective, 2-arm, single-blinded, randomised control trial comparing focused shockwave therapy (f-ESWT) to an ultrasound guided corticosteroid injection. Primary outcome measure was the visual analogue pain score. Secondary outcome measures included the Harris Hip Score (HHS) and Trendelenburg test for function; SF-36 for quality of life (QoL); and a Likert scale question for subjective assessment of symptom improvement.
Results
104 patients (10 males and 94 females), of mean age 61.5 years were recruited. 53 were randomised to receive ESWT and 51 to receive an image-guided injection. 11 patients were lost to follow-up. There were no significant differences in baseline scores between groups. At 3 months, pain, function and QoL scores had improved in both groups but were not statistically significant. The Trendelenburg test was significantly improved in the f-ESWT group with 80% patients being negative compared to 20% at baseline ( p < 0.001). At 12 months, across all outcomes, the ESWT group had significantly improved scores compared to the injection group; VAS 37.1 versus 55.0 ( p = 0.007, 95% confidence interval [CI], 6.3–30.8), HHS 69.7 versus 57.5 ( p = 0.002, 95% CI, −20.0 to −4.6) and SF-36 52.4 versus 47.7 ( p = 0.048, 95% CI, −9.31 to −0.04). The improvement in Trendelenburg test was maintained in the ESWT group, but the injection group had reverted to baseline ( p < 0.001).
Conclusions
We have shown f-ESWT is an effective treatment for patients with GTPS. We would advocate f-ESWT as an effective non-invasive treatment modality for this challenging patient population. Trial Registration No. ISRCTN8338223
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK.
- Keele University, Keele, Staffordshire, UK.
Förderung
- orthopaedic institute limited
Zitieren
APA
Heaver, C., Pinches, M., Kuiper, J. H., Thomas, G., Lewthwaite, S., Burston, B. J., & Banerjee, R. D. (2023). Greater trochanteric pain syndrome: focused shockwave therapy versus an ultrasound guided injection: a randomised control trial. HIP International, 33(3), 490-499. https://doi.org/10.1177/11207000211060396
Vancouver
Heaver C, Pinches M, Kuiper JH, Thomas G, Lewthwaite S, Burston BJ, et al. Greater trochanteric pain syndrome: focused shockwave therapy versus an ultrasound guided injection: a randomised control trial. HIP International. 2023;33(3):490-499. doi:10.1177/11207000211060396
BibTeX
@article{Heaver2023,
author = {Heaver, Catriona and Pinches, Megan and Kuiper, Jan Herman and Thomas, Geraint and Lewthwaite, Simon and Burston, Ben J and Banerjee, Robin D},
title = {Greater trochanteric pain syndrome: focused shockwave therapy versus an ultrasound guided injection: a randomised control trial},
journal = {HIP International},
year = {2023},
volume = {33},
number = {3},
pages = {490--499},
doi = {10.1177/11207000211060396}
}
EUVIMED